LivaNova PLC $LIVN Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. trimmed its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 78.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,118 shares of the company’s stock after selling 36,715 shares during the period. Envestnet Asset Management Inc.’s holdings in LivaNova were worth $456,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after purchasing an additional 407 shares during the last quarter. CWM LLC grew its stake in LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after acquiring an additional 299 shares during the last quarter. Parallel Advisors LLC increased its holdings in LivaNova by 1,312.3% during the 2nd quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after acquiring an additional 958 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in LivaNova by 415.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock valued at $58,000 after acquiring an additional 1,184 shares in the last quarter. Finally, Strs Ohio acquired a new position in LivaNova during the first quarter worth about $130,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on LIVN shares. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a report on Wednesday, September 3rd. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a research report on Wednesday, November 19th. Finally, Mizuho upped their target price on shares of LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $62.43.

LivaNova Stock Performance

LivaNova stock opened at $63.31 on Wednesday. The stock has a fifty day moving average price of $53.64 and a 200 day moving average price of $49.84. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $63.70. The firm has a market capitalization of $3.46 billion, a P/E ratio of -16.28 and a beta of 1.00. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.